InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.490 0.025 (5.38%)+
Announcement
Release
9 Jun 2026 8:35AM
Price at Release
$0.465
Full Release
download
Summary
LTR Pharma has secured its first U.S. commercial agreement for the distribution of ROXUS®, an intranasal treatment for erectile dysfunction, with Shed Holdings LLC, a U.S. direct-to-consumer telehealth platform. The agreement is a binding term sheet that includes a performance-based minimum commercial volume target of 150,000 prescription units during the first 12 months from Commercial Launch. This partnership marks LTR Pharma’s initial entry into the U.S. market, leveraging Shed's consumer-facing platform, Mavrox, as the primary commercialisation and distribution channel. The agreement grants Shed exclusive rights in the U.S. telehealth channel for two years, contingent upon performance criteria. LTR Pharma will begin work on Definitive Agreements and launch readiness activities, aiming to expand its presence in the U.S. men's health market.
Key Points
  • LTR Pharma signs binding term sheet with Shed Holdings LLC.
  • Agreement involves a minimum commercial volume target of 150,000 ROXUS® units in the first 12 months.
  • ROXUS® will be distributed via Mavrox, Shed's telehealth platform.
  • The agreement includes a two-year exclusivity in the U.S. direct-to-consumer telehealth channel.
  • LTR Pharma is the product owner and intellectual property holder.
  • ROXUS® is a rapid-acting intranasal treatment for erectile dysfunction.
  • Deal represents LTR Pharma’s first commercial strategy in the U.S. market.
  • The term sheet will be converted into Definitive Agreements within 60 days.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.